SNAP-8 Dosage, the 63% Study Nobody Can Find, & FDA Status
A cosmetic-industry peptide marketed to relax expression lines by interfering with the same SNARE complex Botox targets, sold as a longer, supposedly stronger follow-up to Argireline. The widely repeated "63% wrinkle reduction" figure traces back to an unpublished, manufacturer-run study. Neither of the two peer-reviewed human trials that actually test this ingredient tests it alone.
Reviewed by the PepGuard team · Last reviewed Jul 28, 2026
Synthetic acetylated octapeptide, an elongated analog of Acetyl Hexapeptide-8 (Argireline) · also sold as Acetyl Octapeptide-3
Photo: Mona Jain / UnsplashA dilution convention, not a dose.
Cosmetic formulators don’t dose SNAP-8, they blend it. The numbers below are what that blending actually works out to.
| What's cited | Range |
|---|---|
| Manufacturer-cited use level (of ~0.05%-active stock solution) | 3-10% of stock solution blended into a finished serum or cream |
| Resulting active-peptide concentration in finished product | ≈0.0015-0.005% w/w peptide, once the stock-solution dilution is accounted for |
| Concentration used in the unpublished manufacturer study behind the "63%" figure | 10% stock solution, applied twice daily to periocular skin for 28 days |
| Application route in every study that exists, published or not | Topical only. No study of any kind has tested subcutaneous or injectable use. |
There is no clinically validated human dose for SNAP-8, and there can't be, since no published trial has tested the isolated peptide on its own. What circulates instead is cosmetic-industry formulation convention: suppliers sell it as a diluted "stock solution" (roughly 0.05% actual peptide), and the commonly cited "3-10%" use level refers to how much of that stock solution to blend into a finished serum or cream, not 3-10% pure peptide. Once that dilution math is worked through, the actual peptide concentration in a finished product is closer to 0.0015-0.005% w/w. This is topical formulation guidance, not a dosing chart for injection, and vendors selling it as an injectable are selling a route of administration nobody has ever studied.
Nobody has tested this peptide alone.
Search “SNAP-8” and you’ll find the same number everywhere: 63% wrinkle-depth reduction. That figure comes from a manufacturer-run study measuring a 10% stock solution applied twice daily for 28 days, using laser-scanned skin imprints from 17 volunteers. It has never been published in a peer-reviewed journal, so nobody outside the company that ran it can check the method, the controls, or the statistics.
The two studies that are peer-reviewed and do mention SNAP-8 by its INCI name, acetyl octapeptide-3, both tested it as one ingredient inside a hyaluronic-acid microneedle patch, alongside vitamin C derivatives, lysophosphatidic acid, or a separate blend of arginine/lysine polypeptide, palmitoyl tripeptide-5, and adenosine. Both patches showed real improvement over placebo. Neither trial can tell you how much of that improvement, if any, came from SNAP-8 specifically, because SNAP-8 was never the only variable. Its predecessor, Argireline, has the isolated trial SNAP-8 doesn’t: a 2002 study testing the hexapeptide alone found a 30% wrinkle-depth reduction after 30 days. That gap, one molecule tested alone, one only tested in a mix, is the whole story here.
Mild, topical, and never tested past 28 days.
| Signal | Frequency | Context |
|---|---|---|
| Skin irritation or redness at the application site | occasionally reported | Consistent with topical cosmetic peptides generally; not specific to SNAP-8's mechanism. |
| Contact sensitization in susceptible individuals | rarely reported | Standard caution for any leave-on cosmetic active; no SNAP-8-specific sensitization study exists. |
| Safety of subcutaneous or intramuscular injection | unknown / not studied | SNAP-8 has never been formulated, dosed, or safety-tested for injection in any published source. Every trial and every manufacturer study is topical. |
| Long-term daily use beyond 28 days | unknown / not studied | The longest published human exposure (in a multi-ingredient microneedle patch) ran 28 days. Nothing published covers ongoing daily use past that window. |
| Effect attributable to SNAP-8 specifically, isolated from other actives | unknown / not studied | Both PubMed-indexed human studies tested SNAP-8 as one ingredient in a multi-active patch (alongside vitamin C derivatives, lysophosphatidic acid, or arginine/lysine polypeptide, palmitoyl tripeptide-5, and adenosine). Neither isolates SNAP-8's individual contribution to the result. |
Regulated as a cosmetic ingredient, not a drug. No FDA premarket approval required or performed.
SNAP-8 isn't reviewed under the same framework as the injectable research peptides elsewhere on this site, because it isn't sold or marketed as a drug. The FDA's own guidance is explicit: under the FD&C Act, "cosmetic products and ingredients do not need FDA premarket approval, with the exception of color additives," and "neither the law nor FDA regulations require specific tests to demonstrate the safety of individual products or ingredients." That means SNAP-8 has never gone through anything resembling the Pharmacy Compounding Advisory Committee review that BPC-157, TB-500, Kisspeptin-10, or DSIP have been subject to, not because it passed a safety bar, but because cosmetic ingredients aren't required to clear one before going on shelves. The manufacturer, not any regulator, is legally responsible for substantiating that it's safe.
Every claim above, traced back.
The Argireline trial SNAP-8 doesn’t have, the two cocktail studies that do mention it, and FDA’s own cosmetics authority page. Click through and check them yourself.
SNAP-8 questions, answered.
Not a published, peer-reviewed one. That figure originates from an in-house manufacturer study (10% stock solution, applied twice daily for 28 days), not a study indexed on PubMed. The two human trials that are peer-reviewed and do mention SNAP-8 (as "acetyl octapeptide-3") both tested it as one ingredient inside a multi-active microneedle patch, alongside vitamin C derivatives and other peptides, so neither can isolate what SNAP-8 alone contributed.
SNAP-8 (acetyl octapeptide-3) is a two-amino-acid-longer version of Argireline (acetyl hexapeptide-8), both designed to compete with SNAP-25 in the SNARE complex and reduce acetylcholine-driven muscle contraction. Argireline has an actual isolated human trial behind it (Blanes-Mira et al., 2002: 30% wrinkle-depth reduction after 30 days, tested alone, not in a cocktail). SNAP-8 doesn't have an equivalent standalone trial.
That's the wrong question for this ingredient. SNAP-8 is regulated as a cosmetic ingredient, not a drug, and under the FD&C Act, cosmetic ingredients don't require FDA premarket approval at all (color additives are the only exception). It was never submitted for the kind of compounding safety review that BPC-157 or Kisspeptin-10 have gone through, because that review doesn't apply to cosmetics.
No published source, manufacturer or academic, has ever tested SNAP-8 by injection. Every study and every formulation guideline covers topical use only. A vendor selling it as an injectable is selling a route of administration with zero safety or efficacy data behind it, for any dose.
Industry convention is 3-10% of a supplier's pre-diluted stock solution (about 0.05% active peptide) mixed into a finished serum or cream, which works out to roughly 0.0015-0.005% actual peptide in the product you'd apply. That's a formulation convention, not a clinically established effective dose.
Keep researching.
This is a preview of the SNAP-8 report.
Create your account to check any peptide against the full research base.